Radek Kucera1, Inka Treskova2, Jindra Vrzalova1, Sarka Svobodova1, Ondrej Topolcan3, Radka Fuchsova1, Milena Rousarova1, Vladislav Treska4, Tomas Kydlicek2. 1. Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic. 2. Department of Plastic Surgery, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic. 3. Laboratory of Immunoanalysis, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic topolcan@fnplzen.cz. 4. Department of Surgery, Faculty Hospital in Pilsen, Faculty of Medicine in Pilsen, Charles University in Prague, Pilsen, Czech Republic.
Abstract
BACKGROUND/AIM: There were two aims in the present study. The first was to evaluate the usefulness of insulin-like growth factor 1 (IGF1) for melanoma detection. The second was to correlate changes of serum levels of IGF1 with the Breslow score and sentinel node metastasis positivity. PATIENTS AND METHODS: We examined a group of 216 cases, 77 patients with melanomas and 139 healthy probands. We determined the serum IGF1 levels of each patient using an IRMA radioisotope IGF1 assay kit. Serum samples were collected prior to surgery or any other form of treatment. All melanoma diagnoses were histologically verified. RESULTS AND DISCUSSION: Based on the statistical evaluation between the melanoma group and group of healthy individuals, we observed statistically significant differences in IGF1 serum levels. The median IGF1 levels in the melanoma group was 154.1 ng/ml compared to 111.2 ng/ml in the group of healthy individuals (p=0.0036). The changes of the IGF1 levels related to the Breslow score categories were statistically significant (p=0.0027). Lastly, we compared the results between the positive and negative metastatic affection of the sentinel nodes. The median IGF1 levels in the negative group was 173.5 ng/ml compared to 205.8 ng/ml in the positive group. This difference was statistically significant (p=0.0407). CONCLUSION: Serum levels of IGF1 were significantly higher in patients diagnosed with melanoma compared to the healthy control group. The changes of the IGF1 levels related to the Breslow score categories were statistically significant. Serum levels of IGF1 were significantly higher in the group with the positive metastatic affection of the sentinel nodes than in negative patients. Copyright
BACKGROUND/AIM: There were two aims in the present study. The first was to evaluate the usefulness of insulin-like growth factor 1 (IGF1) for melanoma detection. The second was to correlate changes of serum levels of IGF1 with the Breslow score and sentinel node metastasis positivity. PATIENTS AND METHODS: We examined a group of 216 cases, 77 patients with melanomas and 139 healthy probands. We determined the serum IGF1 levels of each patient using an IRMA radioisotope IGF1 assay kit. Serum samples were collected prior to surgery or any other form of treatment. All melanoma diagnoses were histologically verified. RESULTS AND DISCUSSION: Based on the statistical evaluation between the melanoma group and group of healthy individuals, we observed statistically significant differences in IGF1 serum levels. The median IGF1 levels in the melanoma group was 154.1 ng/ml compared to 111.2 ng/ml in the group of healthy individuals (p=0.0036). The changes of the IGF1 levels related to the Breslow score categories were statistically significant (p=0.0027). Lastly, we compared the results between the positive and negative metastatic affection of the sentinel nodes. The median IGF1 levels in the negative group was 173.5 ng/ml compared to 205.8 ng/ml in the positive group. This difference was statistically significant (p=0.0407). CONCLUSION: Serum levels of IGF1 were significantly higher in patients diagnosed with melanoma compared to the healthy control group. The changes of the IGF1 levels related to the Breslow score categories were statistically significant. Serum levels of IGF1 were significantly higher in the group with the positive metastatic affection of the sentinel nodes than in negative patients. Copyright
Authors: Kathryn E Bradbury; Paul N Appleby; Sarah J Tipper; Ruth C Travis; Naomi E Allen; Marina Kvaskoff; Kim Overvad; Anne Tjønneland; Jytte Halkjaer; Iris Cervenka; Yahya Mahamat-Saleh; Fabrice Bonnet; Rudolf Kaaks; Renée T Fortner; Heiner Boeing; Antonia Trichopoulou; Carlo La Vecchia; Alexander J Stratigos; Domenico Palli; Sara Grioni; Giuseppe Matullo; Salvatore Panico; Rosario Tumino; Petra H Peeters; H Bas Bueno-de-Mesquita; Reza Ghiasvand; Marit B Veierød; Elisabete Weiderpass; Catalina Bonet; Elena Molina; José M Huerta; Nerea Larrañaga; Aurelio Barricarte; Susana Merino; Karolin Isaksson; Tanja Stocks; Ingrid Ljuslinder; Oskar Hemmingsson; Nick Wareham; Kay-Tee Khaw; Marc J Gunter; Sabina Rinaldi; Konstantinos K Tsilidis; Dagfinn Aune; Elio Riboli; Timothy J Key Journal: Int J Cancer Date: 2018-12-07 Impact factor: 7.396